See more : Carel Industries S.p.A. (0YQA.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kamada Ltd. (KMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kamada Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- DongGuan YuTong Optical Technology Co.,Ltd. (300790.SZ) Income Statement Analysis – Financial Results
- Tera Autotech Corporation (6234.TWO) Income Statement Analysis – Financial Results
- Tern Properties Company Limited (0277.HK) Income Statement Analysis – Financial Results
- Wheels Up Experience Inc. (UP-WT) Income Statement Analysis – Financial Results
- Amseco Exploration Ltd. (AXPRF) Income Statement Analysis – Financial Results
Kamada Ltd. (KMDA)
About Kamada Ltd.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.52M | 129.34M | 103.64M | 133.25M | 127.19M | 114.47M | 102.83M | 77.49M | 70.11M | 71.93M | 70.62M | 72.68M | 55.92M | 36.27M | 14.98M | 15.21M | 13.44M |
| Cost of Revenue | 87.03M | 82.64M | 73.31M | 85.69M | 77.45M | 73.00M | 70.74M | 55.84M | 54.11M | 56.31M | 44.22M | 49.98M | 40.20M | 30.20M | 15.83M | 15.14M | 10.28M |
| Gross Profit | 55.49M | 46.70M | 30.33M | 47.55M | 49.74M | 41.47M | 32.09M | 21.65M | 16.01M | 15.62M | 26.41M | 22.69M | 15.72M | 6.07M | -847.15K | 70.83K | 3.16M |
| Gross Profit Ratio | 38.94% | 36.11% | 29.26% | 35.69% | 39.11% | 36.23% | 31.21% | 27.94% | 22.83% | 21.72% | 37.39% | 31.23% | 28.11% | 16.74% | -5.66% | 0.47% | 23.52% |
| Research & Development | 13.93M | 13.17M | 11.36M | 13.61M | 13.06M | 9.75M | 11.97M | 16.25M | 16.53M | 16.03M | 12.75M | 11.82M | 11.03M | 9.76M | 0.00 | 12.37M | 0.00 |
| General & Administrative | 18.25M | 12.80M | 12.64M | 10.14M | 9.19M | 8.53M | 8.27M | 7.64M | 7.04M | 7.59M | 7.86M | 4.41M | 4.82M | 4.78M | 13.83M | 4.11M | 16.63M |
| Selling & Marketing | 9.20M | 15.28M | 6.28M | 4.52M | 4.37M | 3.63M | 4.40M | 3.24M | 3.86M | 2.90M | 2.10M | 1.85M | 2.19M | 2.26M | 236.80K | 631.68K | 196.59K |
| SG&A | 27.45M | 28.09M | 18.91M | 14.66M | 13.56M | 12.16M | 12.67M | 10.89M | 10.90M | 10.49M | 9.96M | 6.26M | 7.01M | 7.04M | 14.07M | 4.74M | 16.83M |
| Other Expenses | 4.04M | 912.00K | 753.00K | 49.00K | 330.00K | 997.00K | 649.00K | 712.00K | 524.00K | 455.00K | 444.00K | 373.00K | 0.00 | 0.00 | 749.21K | 0.00 | 1.10M |
| Operating Expenses | 45.43M | 42.17M | 31.02M | 28.32M | 26.95M | 22.21M | 24.64M | 27.13M | 27.43M | 26.52M | 22.71M | 18.46M | 18.04M | 16.81M | 14.82M | 17.11M | 17.93M |
| Cost & Expenses | 132.46M | 124.81M | 104.34M | 114.01M | 104.40M | 95.21M | 95.38M | 82.98M | 81.54M | 82.83M | 66.92M | 68.44M | 58.24M | 47.01M | 30.65M | 32.26M | 28.21M |
| Interest Income | 588.00K | 91.00K | 295.00K | 1.03M | 1.15M | 820.00K | 500.00K | 469.00K | 463.00K | 1.61M | 289.00K | 578.00K | 2.62M | 589.63K | 116.42K | 85.25K | 216.82K |
| Interest Expense | 1.30M | 914.00K | 1.28M | 266.00K | 293.00K | 340.00K | 162.00K | 126.00K | 934.00K | 3.09M | 3.15M | 3.36M | 3.79M | 5.03M | 4.04M | 4.60M | 442.71K |
| Depreciation & Amortization | 11.47M | 11.61M | 5.83M | 5.25M | 4.66M | 3.56M | 3.65M | 3.36M | 3.23M | 2.79M | 3.00M | 3.04M | 2.86M | 2.78M | 2.47M | 2.37M | 2.13M |
| EBITDA | 21.53M | 4.53M | 5.20M | 25.41M | 27.30M | 23.46M | 11.25M | -1.98M | -7.10M | -8.31M | 8.09M | 7.18M | 2.72M | -9.38M | -15.52M | -14.67M | -20.33M |
| EBITDA Ratio | 15.11% | 8.13% | 5.02% | 18.88% | 22.37% | 20.78% | 11.15% | -1.95% | -11.03% | -9.04% | 9.90% | 10.81% | 5.64% | -21.93% | -87.98% | -96.45% | -93.31% |
| Operating Income | 10.06M | -1.64M | -401.00K | 19.24M | 22.78M | 19.26M | 7.44M | -5.84M | -11.42M | -10.90M | 3.70M | 4.24M | -2.32M | -10.73M | -16.37M | -17.04M | -16.32M |
| Operating Income Ratio | 7.06% | -1.27% | -0.39% | 14.44% | 17.91% | 16.82% | 7.24% | -7.54% | -16.29% | -15.16% | 5.24% | 5.83% | -4.14% | -29.59% | -109.31% | -112.02% | -121.42% |
| Total Other Income/Expenses | -1.64M | -6.79M | -1.19M | -672.00K | 197.00K | 1.08M | -274.00K | 470.00K | 154.00K | -1.68M | -3.23M | -3.46M | -1.18M | -4.44M | -5.66M | 4.60M | -6.58M |
| Income Before Tax | 8.43M | -2.26M | -1.89M | 18.57M | 22.98M | 20.34M | 7.17M | -5.01M | -11.27M | -12.58M | 467.00K | 783.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Income Before Tax Ratio | 5.91% | -1.75% | -1.82% | 13.93% | 18.07% | 17.77% | 6.97% | -6.47% | -16.07% | -17.49% | 0.66% | 1.08% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| Income Tax Expense | 145.00K | 62.00K | 345.00K | 1.43M | 730.00K | -1.96M | 269.00K | 1.72M | -154.00K | 52.00K | 24.00K | 523.00K | 3.79M | 4.44M | 5.66M | -4.60M | 8.13M |
| Net Income | 8.28M | -2.32M | -2.23M | 17.14M | 22.25M | 22.30M | 6.90M | -6.73M | -11.27M | -12.64M | 443.00K | 260.00K | -3.49M | -15.17M | -22.03M | -12.45M | -22.90M |
| Net Income Ratio | 5.81% | -1.79% | -2.15% | 12.86% | 17.49% | 19.48% | 6.71% | -8.69% | -16.07% | -17.57% | 0.63% | 0.36% | -6.25% | -41.83% | -147.09% | -81.81% | -170.39% |
| EPS | 0.17 | -0.05 | -0.05 | 0.42 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| EPS Diluted | 0.15 | -0.05 | -0.05 | 0.41 | 0.57 | 0.55 | 0.18 | -0.18 | -0.31 | -0.35 | 0.01 | 0.01 | -0.13 | -0.61 | -0.88 | -0.94 | -2.16 |
| Weighted Avg Shares Out | 48.83M | 44.82M | 44.77M | 44.14M | 40.32M | 40.28M | 37.97M | 36.42M | 36.25M | 35.71M | 32.71M | 28.08M | 27.55M | 25.06M | 25.06M | 13.20M | 10.61M |
| Weighted Avg Shares Out (Dil) | 53.68M | 44.82M | 44.77M | 44.59M | 40.58M | 40.54M | 38.05M | 36.43M | 36.25M | 35.97M | 33.39M | 28.69M | 27.70M | 25.06M | 25.06M | 13.20M | 10.61M |
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
Kamada: Kedrion Deal Locks In Growth
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Celebrating Seeking Alpha's New Analysts - November 2023 Edition
Kamada: Solid Specialty Plasma Play
Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Source: https://incomestatements.info
Category: Stock Reports